Cyclin-dependent kinase 5 stabilizes hypoxia-inducible factor-1α: A novel approach for inhibiting angiogenesis in hepatocellular carcinoma

Oncotarget

Volumn 7, Issue 19, 2016, Pages 27108-27121

  Herzog, Julia ^a   Ehrlich, Sandra ^a   Pfitzer, Lisa ^a   Liebl, Johanna ^a   Fröhlich, Thomas ^a   Arnold, Georg J ^a   Mikulits, Wolfgang ^b   Haider, Christine ^b   Vollmar, Angelika ^a   Zahler, Stefan ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Angiogenesis; CDK5; HCC; HIF 1

Indexed keywords

CYCLIN DEPENDENT KINASE 5; EPHRIN A1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEASOME; SERINE; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; CDK5 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; BIOASSAY; BLOOD VESSEL PARAMETERS; CELL NUCLEUS; CONTROLLED STUDY; CORRELATIONAL STUDY; ENDOTHELIUM CELL; ENZYME DEGRADATION; ENZYME INHIBITION; EPHRINA1 GENE; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; KINASE ASSAY; LIVER; LIVER CANCER CELL LINE; LIVER CELL CARCINOMA; MASS SPECTROMETRY; MICROARRAY ANALYSIS; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE ASSAY; SITE DIRECTED MUTAGENESIS; TUMOR VASCULARIZATION; VASCULAR DENSITY; VEGFA GENE; VEGFR1 GENE; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; DISEASE MODEL; FEMALE; GENETICS; HEP-G2 CELL LINE; LIVER TUMOR; MALE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NUCLEOTIDE SEQUENCE; PROTEIN STABILITY; RNA INTERFERENCE; SCID MOUSE; SEQUENCE HOMOLOGY; TUMOR CELL LINE; VASCULARIZATION; XENOGRAFT;

ANIMALS; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 5; DISEASE MODELS, ANIMAL; FEMALE; HEP G2 CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIVER NEOPLASMS; MALE; MICE, INBRED C57BL; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN STABILITY; RNA INTERFERENCE; SEQUENCE HOMOLOGY, NUCLEIC ACID; TRANSPLANTATION, HETEROLOGOUS;

EID: 84968764875     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8342     Document Type: Article

References (46)

1. Lew J, Beaudette K, Litwin CM and Wang JH. Purification and characterization of a novel proline-directed protein kinase from bovine brain. J Biol Chem. 1992; 267:13383-13390.
2. Liebl J, Furst R, Vollmar AM and Zahler S. Twice switched at birth: cell cycle-independent roles of the "neuronspecific" cyclin-dependent kinase 5 (Cdk5) in non-neuronal cells. Cell Signal. 2011; 23:1698-1707.
3. Demelash A, Rudrabhatla P, Pant HC, Wang X, Amin ND, McWhite CD, Naizhen X and Linnoila RI. Achaete-scute homologue-1 (ASH1) stimulates migration of lung cancer cells through Cdk5/p35 pathway. Mol Biol Cell. 2012; 23:2856-2866.
4. Feldmann G, Mishra A, Hong SM, Bisht S, Strock CJ, Ball DW, Goggins M, Maitra A and Nelkin BD. Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling. Cancer Res. 2010; 70:4460-4469.
5. Pozo K, Castro-Rivera E, Tan C, Plattner F, Schwach G, Siegl V, Meyer D, Guo A, Gundara J, Mettlach G, Richer E, Guevara JA, Ning L, Gupta A, Hao G, Tsai LH, et al. The role of Cdk5 in neuroendocrine thyroid cancer. Cancer cell. 2013; 24:499-511.
6. Ehrlich SM, Liebl J, Ardelt MA, Lehr T, De Toni EN, Mayr D, Brandl L, Kirchner T, Zahler S, Gerbes AL and Vollmar AM. Targeting cyclin dependent kinase 5 in hepatocellular carcinoma -a novel therapeutic approach. J Hepatol. 2015.
7. Liebl J, Weitensteiner SB, Vereb G, Takacs L, Furst R, Vollmar AM and Zahler S. Cyclin-dependent kinase 5 regulates endothelial cell migration and angiogenesis. J Biol Chem. 2010; 285:35932-35943.
8. Berberich N, Uhl B, Joore J, Schmerwitz UK, Mayer BA, Reichel CA, Krombach F, Zahler S, Vollmar AM and Furst R. Roscovitine blocks leukocyte extravasation by inhibition of cyclin-dependent kinases 5 and 9. British journal of pharmacology. 2011; 163:1086-1098.
9. Liebl J, Zhang S, Moser M, Agalarov Y, Demir CS, Hager B, Bibb JA, Adams RH, Kiefer F, Miura N, Petrova TV, Vollmar AM and Zahler S. Cdk5 controls lymphatic vessel development and function by phosphorylation of Foxc2. Nature communications. 2015; 6:7274.
10. Bergers G and Hanahan D. Modes of resistance to antiangiogenic therapy. Nat Rev Cancer. 2008; 8:592-603.
11. Giuliano S and Pages G. Mechanisms of resistance to antiangiogenesis therapies. Biochimie. 2013; 95:1110-1119.
12. Li S, Yao D, Wang L, Wu W, Qiu L, Yao M, Yao N, Zhang H, Yu D and Ni Q. Expression characteristics of hypoxiainducible factor-1alpha and its clinical values in diagnosis and prognosis of hepatocellular carcinoma. Hepat Mon. 2011; 11:821-828.
13. Miura H, Miyazaki T, Kuroda M, Oka T, Machinami R, Kodama T, Shibuya M, Makuuchi M, Yazaki Y and Ohnishi S. Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J Hepatol. 1997; 27:854-861.
14. Poon RT, Ho JW, Tong CS, Lau C, Ng IO and Fan ST. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg. 2004; 91:1354-1360.
15. Pang RW and Poon RT. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology. 2007; 72 Suppl 1:30-44.
16. Wrzesinski SH, Taddei TH and Strazzabosco M. Systemic therapy in hepatocellular carcinoma. Clin Liver Dis. 2011; 15:423-441, vii-x.
17. Lu KV and Bergers G. Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma. CNS Oncol. 2013; 2:49-65.
18. Ebos JM, Lee CR, Christensen JG, Mutsaers AJ and Kerbel RS. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci U S A. 2007; 104:17069-17074.
19. Wilson GK, Tennant DA and McKeating JA. Hypoxia inducible factors in liver disease and hepatocellular carcinoma: current understanding and future directions. J Hepatol. 2014; 61:1397-1406.
20. Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012; 148:399-408.
21. Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer cell. 2014; 26:605-622.
22. Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N, Inagaki M, Delcros JG and Moulinoux JP. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem. 1997; 243:527-536.
23. Tardio JC. CD34-reactive tumors of the skin. An updated review of an ever-growing list of lesions. J Cutan Pathol. 2009; 36:89-102.
24. Haider C, Grubinger M, Reznickova E, Weiss TS, Rotheneder H, Miklos W, Berger W, Jorda R, Zatloukal M, Gucky T, Strnad M, Krystof V and Mikulits W. Novel inhibitors of cyclin-dependent kinases combat hepatocellular carcinoma without inducing chemoresistance. Mol Cancer Ther. 2013; 12:1947-1957.
25. Liao D and Johnson RS. Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev. 2007; 26:281-290.
26. Antoniou X, Gassmann M and Ogunshola OO. Cdk5 interacts with Hif-1alpha in neurons: a new hypoxic signalling mechanism? Brain Res. 2011; 1381:1-10.
27. Iida H, Honda M, Kawai HF, Yamashita T, Shirota Y, Wang BC, Miao H and Kaneko S. Ephrin-A1 expression contributes to the malignant characteristics of (alpha)-fetoprotein producing hepatocellular carcinoma. Gut. 2005; 54:843-851.
28. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127:2893-2917.
29. Zhu AX, Duda DG, Sahani DV and Jain RK. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol. 2011; 8:292-301.
30. Ribatti D, Vacca A, Nico B, Sansonno D and Dammacco F. Angiogenesis and anti-angiogenesis in hepatocellular carcinoma. Cancer Treat Rev. 2006; 32:437-444.
31. Ribatti D, Vacca A and Dammacco F. The role of the vascular phase in solid tumor growth: a historical review. Neoplasia. 1999; 1:293-302.
32. Pang R and Poon RT. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett. 2006; 242:151-167.
33. Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci. 2012; 33:207-214.
34. Ke Q and Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol. 2006; 70:1469-1480.
35. Brahimi-Horn C, Mazure N and Pouyssegur J. Signalling via the hypoxia-inducible factor-1alpha requires multiple posttranslational modifications. Cell Signal. 2005; 17:1-9.
36. Xie W, Wang H, He Y, Li D, Gong L and Zhang Y. CDK5 and its activator P35 in normal pituitary and in pituitary adenomas: relationship to VEGF expression. Int J Biol Sci. 2014; 10:192-199.
37. Manohar SM, Padgaonkar AA, Jalota-Badhwar A, Rao SV and Joshi KS. Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1alpha and induces G2/M arrest under hypoxia in prostate cancer cells. Prostate Cancer Prostatic Dis. 2012; 15:15-27.
38. McMillin DW, Delmore J, Negri J, Buon L, Jacobs HM, Laubach J, Jakubikova J, Ooi M, Hayden P, Schlossman R, Munshi NC, Lengauer C, Richardson PG, Anderson KC and Mitsiades CS. Molecular and cellular effects of multitargeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications. British journal of haematology. 2011; 152:420-432.
39. Dimova EY, Michiels C and Kietzmann T. Kinases as upstream regulators of the HIF system: their emerging potential as anti-cancer drug targets. Curr Pharm Des. 2009; 15:3867-3877.
40. Warfel NA, Dolloff NG, Dicker DT, Malysz J and El-Deiry WS. CDK1 stabilizes HIF-1alpha via direct phosphorylation of Ser668 to promote tumor growth. Cell Cycle. 2013; 12:3689-3701.
41. Cam H, Easton JB, High A and Houghton PJ. mTORC1 signaling under hypoxic conditions is controlled by ATMdependent phosphorylation of HIF-1alpha. Mol Cell. 2010; 40:509-520.
42. Jiang BH, Zheng JZ, Leung SW, Roe R and Semenza GL. Transactivation and inhibitory domains of hypoxiainducible factor 1alpha. Modulation of transcriptional activity by oxygen tension. J Biol Chem. 1997; 272:19253-19260.
43. Zatloukal M, Jorda R, Gucky T, Reznickova E, Voller J, Pospisil T, Malinkova V, Adamcova H, Krystof V and Strnad M. Synthesis and in vitro biological evaluation of 2,6,9-trisubstituted purines targeting multiple cyclindependent kinases. Eur J Med Chem. 2013; 61:61-72.
44. Kriegl L, Jung A, Engel J, Jackstadt R, Gerbes AL, Gallmeier E, Reiche JA, Hermeking H, Rizzani A, Bruns CJ, Kolligs FT, Kirchner T, Goke B and De Toni EN. Expression, cellular distribution, and prognostic relevance of TRAIL receptors in hepatocellular carcinoma. Clin Cancer Res. 2010; 16:5529-5538.
45. Weitensteiner SB, Liebl J, Krystof V, Havlicek L, Gucky T, Strnad M, Furst R, Vollmar AM and Zahler S. Trisubstituted pyrazolopyrimidines as novel angiogenesis inhibitors. PLoS One. 2013; 8:e54607.
46. Kondo K, Klco J, Nakamura E, Lechpammer M and Kaelin WG, Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer cell. 2002; 1:237-246.